Filing Details

Accession Number:
0001609351-17-000109
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-10-24 16:16:09
Reporting Period:
2017-10-20
Accepted Time:
2017-10-24 16:16:09
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1609351 Spark Therapeutics Inc. ONCE Biological Products, (No Disgnostic Substances) (2836) 462654405
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1673528 Daniel Faga 3737 Market Street
Suite 1300
Philadelphia PA 19104
Chief Business Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-10-20 6,000 $37.62 6,000 No 4 M Direct
Common Stock Disposition 2017-10-20 6,000 $79.95 0 No 4 S Direct
Common Stock Acquisiton 2017-10-24 1,500 $37.62 1,500 No 4 M Direct
Common Stock Disposition 2017-10-24 1,500 $85.00 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Disposition 2017-10-20 6,000 $0.00 6,000 $37.62
Common Stock Employee Stock Option (right to buy) Disposition 2017-10-24 1,500 $0.00 1,500 $37.62
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
131,500 2026-05-01 No 4 M Direct
130,000 2026-05-01 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2017.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.40 to $80.30, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
  3. 25% vested May 2, 2017 and the remainder vests in equal quarterly installments over the following three years.